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Background: Cervical cancer incidence has decreased over time in England particularly after the introduction of
organized screening. In Portugal, where opportunistic screening has been widely available with only slightly lower
coverage than that of the organized programme in England, rates of cervical cancer have been higher than in
England. We compared the burden of cervical cancer, risk factors and preventive interventions over time in both
countries, to identify elements hindering the further decline in incidence and mortality in Portugal. Methods: We
used joinpoint regression to identify significant changes in rate time-trends. We also analyzed individual-level
Portuguese data on sexual behaviour and human papillomavirus prevalence, and recent aggregate data on
organized and opportunistic screening coverage. We compared published estimates of survival, risk factors and
historical screening coverage for both countries. Results: Despite stable incidence, cervical cancer mortality has
declined in both countries in the last decade. The burden has been 4 cases and 1 death per 100 000 women
annually higher in Portugal than in England. Differences in human papillomavirus prevalence and risk factors
for infection and disease progression do not explain the difference found in cervical cancer incidence. Significant
mortality declines in both countries followed the introduction of different screening policies, although England
showed a greater decline than Portugal over nearly 2 decades after centralizing organized screening. Conclusion:
The higher rates of cervical cancer in Portugal compared to England can be explained by differences in screening
quality and coverage.
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Introduction
Portugal has had higher burden of cervical cancer than England.Several multi-country comparisons have shown that European
countries with poor cervical screening coverage have a higher
cervical cancer burden.1–4 Reasons for the difference are not
obvious because cervical cancer development is multi-factorial and
depends on infection with high-risk human papillomavirus (HPV),
the rate of progression of pre-cancerous lesions and the existence of
preventive interventions such as screening and vaccination.5
Opportunistic screening has reduced cervical cancer mortality in
some countries; however, it is characterized by unnecessarily frequent
screening, heterogeneous quality and poor coverage of underserved
women who may be at highest risk. Well organized programmes
enable high coverage of the target population, adequate follow-up
and equity of access with more efficient resource use but has yet to
be implemented in many European countries.6
Like most western European countries, England has seen a decline
in the burden of cervical cancer following the introduction of cyto-
logical screening in 1964, particularly since screening was centrally
organized in 1988.6
In Portugal, cervical screening was introduced in 1978 but only on
an opportunistic basis, although more recently regional organized
programmes with varying coverage have been initiated. Each
mainland regional health administration (RHA) and the regional
health systems of Azores and Madeira are autonomously responsible
for the provision of any programme. Partially-organized screening
was introduced in 1990 in the Centre region. Fully-organized
programmes have been introduced post-2008 with varied regional
coverage in Alentejo, Algarve, Azores and the North. Lisbon and
Tagus Valley and the Autonomous Region of Madeira have not
implemented such a programme yet.7
Here, we investigate the extent to which screening and other
factors may have driven differences in cervical cancer incidence
between Portugal and England by analyzing estimates and time-
trends in multiple data sets including HPV prevalence, cervical
cancer incidence and mortality, screening coverage, sexual
behaviour and other potential risk factors. We then explore the im-
plications of our results for policy making across Europe.
Methods
Cervical cancer incidence and mortality
European age-standardized rates (EASR) were estimated using the
1976 European Standard Population. Age-standardized incidence
was estimated from individual case data provided for 1998–2010 by
all four Portuguese population-based regional registries (Azores,
Centre, North and South), covering 100% of the population.
National estimates were pooled by weighting the regional age-
specific number of cases by the respective proportion of the
population. For the UK, we used estimates from EUREG and
national statistics databases.8,9
Cervical (and other uterine) cancer mortality and female
population sizes for both countries were obtained from the WHO
mortality database10 and Statistics Portugal.11 Inaccuracies in death
certification were adjusted by reallocating deaths from non-
otherwise specified uterine cancers to cervical cancer.1
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We performed segmented regression to analyze rate trends and
identify trend joinpoints (i.e. calendar years where the slopes of two
linear trends changed). The annual percentage change (APC) was
estimated for each segment fitting a log-linear model with the
Joinpoint software.12
Case-fatality risk
Annual case-fatality risk (CFR) was calculated from incidence and
mortality estimates, as its complement (1-Mortality/Incidence) has
been considered a valid approximation of the 5-year relative survival
for most cancers.13 The two-proportion z-test was used to test
whether these populations’ risks differ significantly.
Cervical cancer survival
We used published 5-year survival estimates from the CONCORD-
214 and the EUROCARE15 studies based on cancer registries data.
HPV prevalence
We estimated age-standardized prevalence of 13 high-risk HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) from the
CLEOPATRE Portugal study which recruited 2165 unvaccinated
women aged 18–64 attending National Health Service (NHS) gynae-
cology, obstetrics and sexually transmitted disease services in 2008/9.16
Age-specific and overall crude prevalence estimates of high-risk HPV
in women attending cervical screening in England were sourced from
a systematic review and meta-analysis of the main pre-vaccination
studies.17
Sexual behaviour
Behavioural risk indicators for HPV infection were estimated from
individual-level data of the 2007 survey on sexual behaviour and
HIV/AIDS in mainland Portugal18 (1860 valid questionnaires from
sexually active women aged 16–65 years). We compared these
estimates with those published from the British National Surveys
of Sexual Attitudes and Lifestyles (Natsal-2 in 1999–2000 16–
44 years old, and Natsal-3 in 2010–12, 16–74 years old).19
Definitions were standardized across the two surveys (additional
information is available on request).
Other risk factors
Published estimates were obtained for risk factors for HPV infection
acquisition, persistence and cervical cancer progression: smoking,20
contraception use,21 fertility,22 male circumcision23 and other
sexually transmitted infections (STIs).24,25 We compared outcomes
from European Union surveillance of human immunodeficiency
virus (HIV), chlamydia, syphilis and gonorrhoea in both countries.
Data on these risk factors were only found for the UK.
Cervical screening
Cervical screening coverage in Portugal prior to the introduction of
organized programmes (2008) was obtained from the literature.26,27
Coverage post-2008 was estimated from aggregate data provided by
RHAs in mainland Portugal. Coverage of opportunistic screening
was derived from the number of conventional cytology tests
reimbursed to contracted laboratories in 2010–14. For England, we
used published screening coverage estimates.28
Results
Cervical cancer incidence
Annual incidence of cervical cancer in Portugal in 1998–2010 ranged
from 11.6 (10.8–12.5)–14.3 (13.4–15.3) per 100 000 women; the
negative linear trend over that time period was not significant
(Supplementary table S1 and figure 1). In England over the same
period, incidence varied between 8.0 (7.7–8.3) and 9.7 (9.4–10.1)
and was similarly stable in the 2000 s. We estimated a positive
APC in 1977–88 followed by a negative APC in 1988–98, but no
evidence of a change in incidence in 1999–2011.
In England, the peak age of cervical cancer incidence has shifted
from after 45 years in the early 1980 s to around 30–45 years in the
late 1990 s. In Portugal, it peaked at 40–49 year olds in 1998–2010
(Supplementary figure S1).
Cervical cancer mortality
For Portugal (1955–2013), we estimated 2 joinpoints in cancer
mortality at 1970 and 1982. There was no evidence of a change in
mortality until 1970, with a decline thereafter (figure 1 and
Supplementary table S1). Three trend periods were estimated for
England with joinpoints in 1964, 1988 and 2006. The APC has
declined since 1950, with the steepest decline in 1988–2006.
In 1998–2010, average cervical cancer incidence in Portugal
exceeded that in England by 4 cases per 100 000 women. However,
cervical cancer mortality was similar between countries (on average
1 more death per 100 000 women annually in Portugal than in
England). Both countries show a period-specific effect as age-
specific rates declined similarly in consecutive periods and birth
cohorts across all age groups apart from the youngest (20–29 and
30–39 years old) (Supplementary figures S2 and S3).
Case-fatality risk and survival
Cervical cancer CFR was higher in England (mean 0.33, range 0.24–
0.40, 1998–2010) compared to Portugal (mean 0.30, range 0.25–0.34,
1998–2010) but the difference was not statistically significant (P> 0.5
every year) (Supplementary figure S4). Also, CFR declined in England
throughout 1996–2011but not in Portugal (Supplementary table S1).
Allemani and colleagues14 found that 5-year net survival improved
from 54% (50–58%) to 62% (60–63%) in Portugal (1998–2009) and
from 58% (57–59%) to 60% (59–62%) in England (1995–2009)
(Supplementary table S2). Similarly, the EUROCARE database
shows a greater improvement of 5-year relative survival in Portugal
[from 58% (56–50%) to 64% (62–66%)] than in England [from 65%
(65–66%) to 67% (66–68%)] between 1995–99 and 2000–07.15
Although similar estimates were found for both countries, slightly
greater survival improvement was reported for Portugal in both
EUROCARE and CONCORD-2 studies, while we found a steeper
decline in CFR for England (Supplementary table S1). Given that
population-based survival estimates from high data quality are
available, our CFR estimates must be considered cautiously and
their complement should not be used instead of 5-year relative
survival estimates.
Human papillomavirus prevalence
High-risk HPV prevalence among unvaccinated women with normal
cytology was 5.5% (95% CI: 3.6–8.9%) in Portugal and 10.4% (4.5–
18.7%) in the UK. The age distribution was similar in both
countries, with peak prevalence at 20–24 years of age, followed by
a decline until age 40 (Supplementary figure S5). The overall crude
high-risk HPV prevalence was similar in England and the UK.
Sexual behaviour
Women’s median age of first heterosexual intercourse was higher in
Portugal (19 years) than in Great Britain (17 years) (Supplementary
table S3). The age difference between partners at start of the rela-
tionship was smaller in Portugal compared with that in Great
Britain, with 76% and 63% being5 years, respectively.
Portuguese women had fewer lifetime partners than British
women, but the number of partners over the last year and the
proportion of women with 1 new partner last year were similar
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in both countries. Portuguese women reported 8% of relationships
lasting less than 1 month, whereas in Great Britain these account for
51% of the relationships. In both countries, over 30% of reported
relationships overlapped.
Overall, Portuguese women were at lower behavioural risk of
acquiring HPV from their partners given their later sexual debut,
fewer number of lifetime partners per year and fewer short-term
relationships.
Other risk factors
Smoking, the number of full-term pregnancies, the use of oral
hormonal contraceptives, and exposure to other STIs have been
associated with cervical cancer. Conversely, there is robust
evidence of inverse association between male circumcision and
HPV acquisition and consequent development of cervical cancer.5
Both Portugal and the UK have shown a decreasing trend in
tobacco use over the last decade,20 with the prevalence of smoking
lower in Portugal than in the UK (Supplementary table S4). The
Portuguese fertility rate was lower in the early 2000 s than in the
UK.22 However, Portugal has higher hormonal contraceptive use,
lower condom use and lower prevalence of male circumcision
compared to the UK.21,23
The UK has higher gonorrhoea and syphilis incidence, whilst
Portugal has higher HIV incidence.24,25 Portugal has no organized
Chlamydia surveillance system so Chlamydia prevalence cannot be
compared with the UK.25
Cervical screening
Cervical screening in Portugal and England differ both in quality and
coverage. There is a 20-year lag between countries in the introduc-
tion of fully-organized programmes (figure 2).
In Portugal, cervical screening remains mainly opportunistic with
lower coverage than in England (figure 3). The proportion of eligible
women aged 25–64 screened between 2012 and 2014 in Portugal was
lower than in England between 1995 and 2015 (average 3-year
coverage 60% vs. 69%, respectively). Despite the introduction of
organized screening post-2008 in Portugal, 3-year coverage of
resident women in 2012–14 (55%) was lower than in 2002–03
(58%). In England, 5-year coverage also decreased over time.
Organized programmes in Portugal 2012–14 covered at most for
40% of resident women aged 25–64; however, the proportion of
eligible women invited for screening via a call/recall system varied
from 6% (the North) to 60% (Alentejo), assuming 10% of resident
women are excluded for clinical reasons7 (Supplementary table S5).
Over the same period, the English NHS Cervical Screening
Programme was available to all resident women aged 25–64, all
eligible women (94% of resident) were invited to participate, and
91% of these were adequately screened.28
Prior to 2008, in both countries, younger women had the lowest par-
ticipation rates among women eligible for cervical screening (aged from
20/25–60/64, depending on the country) (Supplementary figure S6).
Discussion
Since 1998, cervical cancer incidence and mortality has declined in
both Portugal and England, but has been consistently higher in
Portugal1,29 despite higher prevalence for high-risk HPV and risk
factors for cervical cancer (such as sexual activity, smoking and other
STIs besides HIV) in Portugal. Indeed, HPV prevalence in England
exceeds that in Portugal, with the age distributions of HPV
prevalence in the two countries resembling those for Southern and
Northern Europe in 1995–2009.30 HPV vaccination was introduced
in both countries too recently to have had an effect on cervical
cancer incidence as the first vaccinated cohorts reached the
screening age of 25 in 2015. Hence, the higher incidence in
Portugal can only be explained by differences in screening.
Cervical cancer survival in England is similar to that in Portugal,
despite lower incidence. This may be due to screening selectively
preventing the less invasive cancers and to differences in access
and effectiveness of cancer treatment between countries.31
Figure 1 Age-standardized Cervical Cancer Incidence and Mortality by calendar period, EASR. EASR, European age-standardized rate using
the 1976 European Standard Population; dots represent annual incidence estimates; squares represent annual mortality estimates; solid
lines represent linear time-trends obtained by joinpoint regression; dashed lines represent 95% confidence intervals; Incidence data
pertain to England and mortality data pertain to England and Wales
Figure 2 Timeline of main cervical cancer preventive interventions
in Portugal and England. Opportunistic and Organised refer to
screening programmes
Understanding differences in cervical cancer incidence in Western Europe 3 of 5
Downloaded from https://academic.oup.com/eurpub/advance-article-abstract/doi/10.1093/eurpub/ckx176/4558663
by London School of Hygiene & Tropical Medicine user
on 29 January 2018
Registration inaccuracies have hindered trend analyses of cervical
cancer.29 More recently, Allemani and colleagues14 used individual
patient data from all four Portuguese regional cancer registries
(1998–2009) who reported 100% coverage of the national population
and higher overall quality compared to the European average. We
assumed similar quality for the data available to us (1998–2010). We
corrected for inaccuracies in deaths certification following Arbyn and
colleagues’ approach.1 We reproduced their results for Portugal, the
Netherlands, and the UK, and extended the analysis to 2013. The re-
liability of these adjustments is debatable, particularly for Portugal
where the Netherlands have been used as reference country, and
further methodological research is needed. Consequently, our
mortality (and CFR) estimates for Portugal may be underestimates,
and the gap between countries could be even greater. These data limi-
tations highlight the importance of high-quality registry data (which
may reduce the number of deaths classified as being from uterine
cancer not otherwise specified) and effective collaboration between
cancer and screening registries to enable monitoring and evaluating
the effectiveness of preventive interventions.
Our findings support existing recommendations for investment in
well-organized cervical screening programmes.6 Opportunistic
screening may have somewhat reduced cervical cancer mortality in
Portugal but not to the extent seen in England. Time-trends suggest
cervical cancer rates in Portugal would have declined more sharply
had screening been organized. In the UK, incidence and mortality
only declined post-central organization of screening. England (in
contrast to Portugal) has seen reductions in the peak age of
cervical cancer incidence.32
These findings are likely generalizable to other European
countries–most of which have or are implementing organized
programmes, as previous studies showed that the increasing
cohort-specific risk of cervical cancer in Europe (after the 1930–
40 s) was overridden earlier and more pronouncedly in Northern
Europe by the decreasing period-specific risk due to effective
screening.2 Encouraging trends are seen in the Baltic countries
where organized screening has been initiated and incidence is
stabilizing, whilst in Bulgaria and Romania (where screening is
fairly opportunistic) incidence trends are still increasing.33
Widespread opportunistic screening might also be hindering the
extension of coverage of the recently implemented programmes in
Portugal.6,7 Other European countries also in transition to organized
screening (including Belgium, France, Greece, Italy, Spain and many
Eastern European countries) may face similar challenges. Hence,
countries with no screening yet (e.g. Albania, Azerbaijan) may
benefit from thorough planning and implementation of organized
programmes.
Acknowledgements
We thank the help of Pedro Moura Ferreira at the Social Sciences
Institute Portugal; Nuno Miranda and Cristina Portugal at the
National Programme for Oncological Disease, General-Directorate
for Health, Portugal; Tereza Lopes, Filomena Horta Correia,
Fernanda Loureiro, Ana Dinis, and Fernando Tavares at the
regional health administrations of Alentejo, Algarve, Centre,
Lisbon and Tagus Valley, and North; Gonc¸alo Forjaz, Joana
Bastos, Ana Filipa Gonc¸alves, and Alexandra Mayer-da-Silva at the
cancer registries of Azores, Centre, North, and South.
Funding
DM was funded by the Foundation for Science and Technology
(individual PhD studentship SFRH/BD/84974/2012) on behalf of
the Portuguese Ministry of Education and Science and the Human
Potential Operational Programme of the National Strategic
Reference Framework, within the European Social Fund of the
European Commission’s 7th Framework Programme. MJ was part
funded by the National Institute for Health Research Health
Protection Research Unit (NIHR HPRU) in Immunization at the
London School of Hygiene and Tropical Medicine in partnership
with Public Health England (PHE) (grant HPRU-2012-10096). The
views expressed are those of the authors and not necessarily those of
the NHS (England), the NIHR, the Department of Health (England),
Public Health England or NIH Portugal.
Supplementary data
Supplementary data are available at EURPUB online.
Conflicts of interest: None declared.
Key points
 Cervical cancer incidence and mortality have been higher in
Portugal than in England.
 High-risk HPV prevalence, sexual behavioural risk, and the
prevalence of other risk factors for cervical cancer, such as
smoking and other STIs (apart from HIV), have been lower
in Portugal than in England.
 Differences in cervical screening are likely to explain the
higher burden of cervical cancer in Portugal compared to
England.
 Cervical cancer rates in Portugal are likely to have declined
more rapidly had cervical screening been organized earlier.
Figure 3 Screening coverage in women aged 25–64 in Portugal26,27
and England.28 For England, coverage is defined as the proportion of
eligible women aged 25–64 who were screened adequately within
the previous 3.5 or 5 years. For Portugal, white dots represent
coverage as the proportion of resident women aged 25–64 screened
within the previous 3 or 5 years, and black dots represent coverage as
the proportion of eligible women aged 25–64 screened within the
previous 3 years (assuming 10% of resident women are excluded for
clinical reasons7)
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